Saturday, August 25, 2018 12:14:04 PM
"I do have a difficult time explaining how MannKind’s former Chief Commercial Officer[Castagna], who was selected by the Board of Directors for a CEO position in spite of his lackluster results, is still struggling with the effective marketing of Afrezza.
I happen to agree with CEO Castagna that scripts should be in tens of thousands, but I have yet to see any sign whatsoever that he can deliver market acceptance. He may have sold himself to the majority owners and the BoD but he has not sold himself to me or a majority of shareholders.
I’m not prepared to give Castagna full credit for the Kendall hiring either. Castagna was the closing pitcher on that win.
Was he so arrogant that he believed his marketing skills & ideas alone were sufficient to get the job done (via his hiring of specialists) and only now after nearly three years of getting control of Afrezza back from Sanofi he’s putting together a qualified marketing team?
Perhaps he blamed his lack of success on the previous CEO. But now, as CEO, all failure and success must be laid on his shoulders. I believe Afrezza will eventually become successful because of the Kendall hiring. The new marketing team is an unknown at this point. But Castagna, unfortunately, still remains a big unknown to shareholders and to Wall Street."
...but he really did.
Recent MNKD News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/15/2024 09:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/09/2024 02:30:04 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 09:06:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 09:05:13 PM
- MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/07/2024 09:02:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/06/2024 09:04:14 PM
- MannKind to Present at 2024 UBS Healthcare Conference • GlobeNewswire Inc. • 11/05/2024 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/05/2024 02:00:03 AM
- MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases • GlobeNewswire Inc. • 11/04/2024 11:05:00 AM
- MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024 • GlobeNewswire Inc. • 10/31/2024 08:05:00 PM
- More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®) • GlobeNewswire Inc. • 09/30/2024 10:00:00 AM
- MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease • GlobeNewswire Inc. • 09/18/2024 10:15:00 AM
- MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference • GlobeNewswire Inc. • 09/10/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 01:11:49 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 08:25:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 08:35:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:03 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 09:23:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:15:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:15:28 PM
- MannKind to Present at Upcoming Conferences • GlobeNewswire Inc. • 08/27/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:03:59 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM